Explore
Harnessing oncolytic virus-mediated immunity
Philippe Fournier and Volker Schirrmacher
2015
0 Ungluers have
Faved this Work
Login to Fave
Oncolytic viruses (OVs) have emerged as a promising anticancer treatment. OVs selectively infect, replicate in, and kill tumor cells. Oncolytic viral therapy occurs in two phases: an initial phase where the virus mediates direct oncolysis of tumor cells, and a second phase where an induced post-oncolytic immune response continues to mediate tumor destruction and retards progression of the disease. For a long time, the therapeutic efficacy was thought to depend mainly on the direct viral oncolysis based on their tumor selective replication and killing activities. But the post-oncolytic anti-tumor activity induced by the OV therapy is also a key factor for an efficient therapeutic activity. The topic adresses various strategies how to optimize OVs anti-tumor activity.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 129 times via unglue.it ebook links.
- 12 - epub (CC BY) at Unglue.it.
- 11 - epub (CC BY) at Unglue.it.
- 34 - mobi (CC BY) at Unglue.it.
- 27 - epub (CC BY) at Unglue.it.
- 32 - pdf (CC BY) at Unglue.it.
Keywords
- anti-tumor activity
- anti-viral response
- immunotherapeutic approaches
- immunovirotherapy
- medicine
- Oncolytic Virotherapy
- oncolytic virus
- tumor-associated antigen
Links
DOI: 10.3389/978-2-88919-450-6Editions